Welcome address

Dear Colleagues,

On behalf of the Hellenic Oncology Research Group, I welcome you to the fourth annual Best of SABCS® Greece, an aggregation of most current critical findings in breast cancer research presented at the 2018 San Antonio Breast Cancer Symposium®.

The San Antonio Breast Cancer Symposium® is the premier conference for basic, translational, and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world. The Best of SABCS® provides professionals, who were unable to travel to San Antonio, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders.

Principal subject areas of the “Best of SABCS® Greece 2019” program include:

• Practice changing data on the managements of residual disease after neoadjuvant chemotherapy

• Advances in metastatic breast cancer genomics

• Updates in surgery and radiation therapy

• Emerging data on immunotherapy and novel therapeutics.

The San Antonio Breast Cancer Symposium® has always been a forum for interaction between professionals involved with all aspects of breast cancer research and care and it is envisioned that this camaraderie will also be experienced at this year’s Best of SABCS® – Greece”.

There is another reason to join us this year in Athens; to present together the second Hellenic Oncology Research Group award for Lifetime achievements in Breast Cancer Care and congratulate the recipient Dr Eleftherios Mamounas MD, MPH for his extraordinary contributions in the field.

I look forward to welcome you to Athens and wish you a fruitful conference.

Emmanouil Saloustros MD, DSc
 Assoc. Professor of Oncology
 Faculty of Medicine, University of Thessaly
09:30-09:45  M. Piperi
• GS4-05. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003)
• GS4-02. Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials

09:45-10:00  Discussant: V. Kouloulias

10:00-10:15  Discussion - local therapy

10:15-10:30  Coffee Break

10:30-11:20  Session 3: Breast cancer risk and basic science
Chairmen: K. Yannoukakos, N. Xenidis

10:30-10:40  V. Apostolou
• GS2-01. Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study

10:40-10:55  E. Maragouli
• GS1-03. Crosstalk between osteoblasts and breast cancer cells alters breast cancer proliferation through multiple mechanisms
• Clinical utility of circulating tumor cell count as a tool to choose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial
• GS5-07. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

10:55-11:10  E. Fountzila
• GS1-07. The genomic landscape of 501 metastatic breast cancer patients
• GS1-06. Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples

11:10-11:20  Discussion
11:20-12:30  Session 4: Neo-adjuvant therapy and residual disease
Chairmen: C. Panopoulos, TBD

11:20-11:35  I. Litos
- GS2-03. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients
- GS5-05. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state

11:35-11:50  K. Tsigaridas
- GS3-02. PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects ofLetrozole with and without palbociclib.
- KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC).

11:50-12:05  E. Kontopodis
- GS5-06. No survival benefit of chemotherapy escalation in patients with pCR and «high-immune» triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial
- GS1-10. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE

12:05-12:20  Discussant: D. Tryfonopoulos

12:20-12:30  Discussion

12:30-13:25  Session 5: Adjuvant therapy
Chairpersons: TBD, E. Galani

12:30-12:45  A. Karampeazis
- S2-02. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis.
- GS6-04. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study
12:45-13:00 S. Karageorgopoulou
- GS2-05. Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer

13:00-13:15 M. Nikolaou
- GS2-07. PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
- The immunomodulatory potential of denosumab in breast cancer: results from DBEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer

13:15-13:25 Discussion

13:25-14:10 Hellenic Oncology Research Group Award & Lecture
Chairmen: V. Georgoulas, V. Venizelos
- Introduction: I. Athanasiadis
- E. Mamounas
  - Neoadjuvant Chemotherapy in Early Breast Cancer: Discovering Tumor Biology, Individualizing Therapy and Improving Outcomes

14:10-15:00 Lunch break

15:00-15:30 Patient Advocacy session
Chairmen: P. Kosmidis, I. Boukovinas
- C. Mitsi: Talking openly about Metastatic Breast Cancer

15:30-16:00 G. Lamprodimou
- GS3-06. Dynamics of breast cancer relapse reveal molecularly defined late recuring ER-positive subgroups: Results from the METABRIC study
- GS3-03. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

16:00-16:15 A. Isaakidou
- GS3-08. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial
  - nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer
  - SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer

16:15-16:30 Discussion

16:30-17:45 Session 7: Immunotherapy and novel therapeutics
Chairmen: I. Athanasiadis, A. Kotsakis

16:30-16:45 N. Spathas
- A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer (MBC). Lindeman
  - Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Jhaveri
  - Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER positive/HER2-negative metastatic breast cancer previously treated with everolimus. Diamond

16:45-17:00 E. Sogka
- Safety and efficacy of palbociclib and radiotherapy in metastatic breast cancer patients: Initial results of a novel combination
  - Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results
  - Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162)
17:00-17:15  **N. Tsoukalas**
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
- Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
- GS1-04. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer

17:15-17:30  **E. Timotheadou**
- Is breast cancer entering the immunotherapy era?

17:30-17:45  Discussion

17:45-18:00  **Coffee break**

18:00-19:00  **Session 8: Supportive and survivorship issues**
Chairpersons: A. Ardavanis, S. Droufakou

18:00-18:20  **I. Drositis**
- GS5-01. A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab
- GS5-02. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from the EBBA-II trial
- No increased cardiovascular mortality after twenty years in a randomized trial of radiotherapy after breast conserving surgery, SweBCG 91RT, from the Swedish breast cancer group

18:20-18:35  **Z. Saridakis - Zoras**
- GS5-03. Lifestyle intervention and effect on disease-free survival in early breast cancer pts: Interim Analysis from the randomized SUCCESS C study
- GS6-03. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

18:35-18:50  **S. Kokkali**
- GS6-02. A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study 5C-1603
- Impact of BRCA mutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study

18:50-19:00  Discussion

19:00-19:30  **Session 9: What will we do on Monday?**
Chairpersons: N. Androulakis, C. Christodoulou
Speaker: E. Razis

19:30-20:00  **Closing Remarks**
Affiliations

Alexopoulos A. MD, PhD, Medical Oncologist, “HYGEIA” Hospital, Athens
Androulakis N. MD, PhD, Head of the Medical Oncology Dpt., “Venizeleio” General Hospital of Heraklion, Crete
Apostolou V. Molecular Biologist, PhD, Postdoctoral Fellow, Molecular Diagnostics Laboratory, NCSR Demokritos, Athens
Aravantinos A. MD, Director, 1st Dpt. of Medical Oncology, Athens Anti-Cancer Hospital “Agios Savvas”, Athens
Athanasiadis I. Medical Oncologist, Director of Oncology Clinic “MITERA” Hospital, Ass. Professor of Oncology Northwestern University Chicago
Boukouris I. MD, PhD, PharmaD, Head, Oncology Unit, “Bioclinic”, Thessaloniki
Christodoulou C. Medical Oncologist, Director, 2nd Oncology Dpt., “Metropolitan” Hospital, Piraeus
Christopoulos A. MD, PhD, Medical Oncologist, Director of the Oncology Unit, “St. Andrews” General Hospital of Patras
Drositis I. MD, PhD, MSc, Post-Doc U.C.L.A., Consultant Medical Oncologist “Venizeleion-Pa.g.n.i.” Hospital, Crete
Droufakos S. MD, Consultant Medical Oncologist, Medical Oncology Dpt., “Hipokokration” Hospital, Athens
Fountzila E. MD, PhD, Medical Oncologist, Euromedica Clinic, Thessaloniki
Galanis E. MD, PhD, Medical Oncologist, “Metropolitan” Hospital, Athens
Georgoulas V. Emeritus Professor of Medical Oncology, School of Medicine, University of Crete
Isaakidou A. Registrar in Medical Oncology, University Hospital of Larissa
Kalogeridi M.A. MD, PhD, Radiation Oncologist, “Alexandra” Hospital, Athens
Kanara M. MD, PhD, FEBS, Consultant Breast Surgeon, Trikala
Karageorgopoulou S. MD, PhD, Medical Oncologist, “IASO” Clinic, Athens
Karampeazis A. MD, PhD, Consultant Medical Oncology, 401 Army General Hospital, Athens
Kokkali S. MD, MSc, Consultant Medical Oncologist, 1st Dpt. of Medical Oncology, “St. Savvas” Anti-Cancer Hospital, Athens
Kantopoulos E. MD, Medical Oncologist, “Venizeleion” General Hospital of Heraklion, Crete
Kontos M. Associate Professor in Breast and General Surgery, National and Kapodistrian University of Athens
Kosmidis P. MD, Director, 2nd Dpt. of Medical Oncology, “HYGEIA” Hospital, Athens
Kotsakis A. MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, Director of the Dpt. of Medical Oncology, General University Hospital of Larissa
Kouloulis V. Associate Professor of Radiation Oncology, National and Kapodistrian University of Athens
Kouroussis C. MD, PhD, Head of the Medical Oncology Dpt., General Hospital “Iasis”, Chania
Kyriasis G. MD, PhD, Professor of Radiation Oncology, Head Radiation Oncology Dpt., School of Medicine, University of Thessaly, Larissa
Lampredimou G. MD, Consultant Medical Oncologist, Oncology Dpt., General Hospital of Larissa
Litos I. Resident of Oncology, Oncology Dpt., University of Thessaly, Larissa
Mamounas E. MD, MPH, Medical Director, Comprehensive Breast Program, Orlando Health UF Health Cancer Center, USA
Maragouli E. MD, Medical Oncologist, University Department of Oncology, Larissa
Mitsi C. MSc Psychologist - Programs Director, Hellenic Association of Women with Breast Cancer “Alma Zois”, Athens
Natsiopoulos I. MD, FEBS-BS, Consultant Breast Surgeon, Thessaloniki
Nikolaou M. MD, MSc, PhD, Medical Oncologist, Oncology Unit, General & Maternity Hospital “Helena Venizelou”, Athens
Panopoulos C. MD, PhD, Medical Oncologist, Director of 4th Dpt. of Medical Oncology, Ercollinik Athens
Piperi M. MD, PhD, Radiation Oncologist, Assistant Chief of Staff, “Iatropolis” Radiotherapy-Radiotherapy, Athens
Pissokas G. MD, PhD, Radiation Oncologist, Head of the Dpt. of Radiation Oncology, “Alexandra” Hospital, Athens
Poulakis F. MD, PhD, FEBS (breast surgery) Head of Breast Surgery Clinic, Euroclinic Athens Hospital
Razis E. MD, PhD, Medical Oncologist, Director of Contemporary Oncology Team, Director of 3rd Oncology Dpt., “HYGEIA” Hospital, Athens
Saridak-Zoras Z. MD, PhD, Medical Oncologist, Scientific Director of the Oncology Dpt. “Asklepios”, Heraklion, Crete
Sokka E. Resident in Medical Oncology, Department of Medical Oncology, University Hospital of Larissa
Spathas N. Medical Oncologist in training, B’ Dpt. of Internal Medicine, “AIFTIKON” University Hospital, Athens
Tepetes K. MD, ScD,FACS, FEBS (Surg Oncol), Professor of Surgery, University of Thessaly Medical School, Larissa
Timoteadou E. Assistant Professor in Medicine & Oncology, Aristotle University of Thessaloniki
Tryfonopoulos D. MD, MSc, PhD, Medical Oncologist, Anti-Cancer Hospital “Agios Savvas”, Athens
Tsigradis K. MD, Medical Oncologist, Assistant Director of Oncology Clinic, Athens Medical Center
Tsoukalas N. MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Consultant at Veterans Hospital (417 NIMITS), Athens
Venizelos V. MD, Director, Breast Service, Dpt. of Surgery, “Metropolitan” Hospital, Piraeus
Xenidis N. MD, PhD, Assistant Professor of Clinical Oncology, Democritus University of Thrace, University Hospital of Alexandroupolis
Yannourakos K. Director of Research, Molecular Diagnostics Laboratory, NCSR Demokritos, Athens
General Information

Organized by

Symposium Venue
Royal Olympic Hotel
28-34 Athanasiou Diakou Str.
117 43, Athens, GREECE
Tel.: +30 210 92.88.400
Fax.: +30 210 92.33.317
E-mail: info@royalolympic.com

Under the auspices of

Registration Fees
Free

Official Language
The official language of the meeting is Greek.

Certificate of attendance
Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program.

Symposium Secretariat

eventema

Congress & Event Planning
2-4, Kastriotou Str.,
Athens - Greece, 11476
tel. +30 210 7294559
e-mail: info@eventema.gr

<table>
<thead>
<tr>
<th>Registration Fees</th>
<th>Certificate of attendance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free</td>
<td>Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program.</td>
</tr>
</tbody>
</table>